X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Megapharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 11, 2020
Details:
This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lurbinectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Jazz Pharmaceuticals
Deal Size: $1,000.0 million Upfront Cash: $200.0 million
Deal Type: Licensing Agreement January 22, 2020
Details:
PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
